Pugliese, D., Felice, C., Landi, R., Papa, A., Guidi, L., & Armuzzi, A. (2016). Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug Healthc Patient Saf.
シカゴスタイル引用形Pugliese, Daniela, Carla Felice, Rosario Landi, Alfredo Papa, Luisa Guidi, , Alessandro Armuzzi. "Benefit–risk Assessment of Golimumab in the Treatment of Refractory Ulcerative Colitis." Drug Healthc Patient Saf 2016.
MLA引用形式Pugliese, Daniela, et al. "Benefit–risk Assessment of Golimumab in the Treatment of Refractory Ulcerative Colitis." Drug Healthc Patient Saf 2016.
警告: この引用は必ずしも正確ではありません.